Natera, Inc. (NTRA) SEC Filings & Earnings Calls

Accumulated deficit and ongoing losses

“As of June 30, 2026, we had an accumulated deficit of $2.9 billion.” · word for word

Dependence on reimbursement and payer coverage

“Many third-party payers do not currently reimburse for Signatera, in part because Signatera is not yet broadly included in oncology clinical practice guidelines.” · word for word

Concentration of revenue in few products

“We generate the majority of our revenues from the sale of Panorama, our non-invasive prenatal test (NIPT) and Horizon, our genetic carrier screening test.” · word for word

Revenue includes significant estimate changes ($52.3M in Q2 2026) which may introduce volatility.

“Change in estimate of approximately $52.3 million in Q2 2026 in revenue accrual as compared to $45.3 million in Q2 2025.”

Operating expenses growing 21.5% YoY, driven by headcount and clinical trials, may pressure margins if revenue growth slows.

“Total operating expenses for Q2 2026 was $555.3 million, compared to $457.0 million in the same period of the prior year, an increase of 21.5%.”

Potential shareholder dilution from increased equity plan shares.

“Amendment increases shares reserved by 3.2 million.”

Accumulated deficit and ongoing losses

“As of March 31, 2026, we had an accumulated deficit of $2.9 billion.” · word for word

Dependence on reimbursement and payer coverage

“Many third-party payers do not currently reimburse for microdeletions screening in part because there has historically been limited published data.” · word for word

Concentration of revenue in few products

“We generate the majority of our revenues from the sale of Panorama, our non-invasive prenatal test (NIPT) and Horizon, our genetic carrier screening test.” · word for word

Operating losses continue, though narrowing; net loss of $85.1M in Q1 2026.

“Net loss of $85.1 million in Q1 2026.”

Variable interest rate debt exposes company to rising SOFR.

“Debt at 30-day SOFR plus 50 bps.”

Net Loss Persistence

“Net Income (in thousands) (208,160)”

Equity Dilution from Compensation

“Potential dilution from existing outstanding equity awards plus shares available for future awards... totals 14.78% of shares outstanding.” · word for word

Related Party Transactions

“Matthew Rabinowitz... is the chairman of the board and founder of MyOme... we are a beneficial holder of approximately 19.1% of the outstanding shares of MyOme on a fully diluted basis.”

Key Person Dependency

“Our Chief Legal Officer, Daniel Rabinowitz, is the brother of our Executive Chairman, Matthew Rabinowitz.” · word for word

Supplier concentration

“our molecular diagnostics tests are currently only validated to perform on Illumina’s sequencing platform; in addition, Illumina is currently the sole supplier of our sequencers and related reagents” · word for word

Reimbursement risk

“many third-party payers currently have negative coverage determinations or otherwise do not reimburse for microdeletions screening and we expect low reimbursement rates for microdeletions screening to continue” · word for word

Continued losses

“We have incurred net losses each year since our inception in 2003.” · word for word

Competitive pricing pressure

“Some of our competitors’ products and services are sold at a lower price than ours, which could cause sales of our tests and services to decline or force us to reduce our prices.” · word for word

Operating expenses grew 44.6% in FY2025, outpacing revenue growth of 35.9%, driven by headcount and legal costs.

“Total operating expense for the full year 2025 were $1,801.4 million, compared to $1,245.5 million, an increase of 44.6%.” · word for word

Preliminary results subject to audit and final adjustments.

“Preliminary unaudited results; subject to revision.”

Potential dilution from earnout shares and price protection shares.

“Up to 824,583 additional shares may be issuable based on milestones and price protection.”

Integration risk of acquired entity.

“Acquisition of Foresight Diagnostics, a privately held company.”

Litigation liability

“As of September 30, 2025 and December 31, 2024, the Company determined that the aggregate accrual for legal contingencies that are probable and reasonably estimable is approximately $40.8 million and $12.6 million, respectively.” · word for word

Guardant Health verdict

“In November 2024, after trial, the jury returned a verdict finding the Company liable for false advertising and found damages of $292.5 million.” · word for word

Operating expense growth

“Research and development expenses during the nine months ended September 30, 2025, increased by $174.2 million, or 63.4%... Selling, general and administrative expenses increased by $279.6 million, or 46.1%.” · word for word

Dependence on reimbursement

“Our ability to increase our revenues and gross profit will depend on our ability to further penetrate the U.S. market with our direct sales force.” · word for word

Revenue concentration in Medicare

“For the nine months ended September 30, 2025 and 2024, approximately 13.9% and 11.5%, respectively, of total revenue were paid by traditional Medicare on behalf of multiple customers.” · word for word

Operating expenses grew 54.9% in Q3, outpacing revenue growth of 34.7%, driven by headcount and legal costs.

“Total operating expenses increased 54.9% to $482.0 million.”

Net loss widened to $87.5M from $31.6M in Q3 2024.

“Net loss of $87.5 million vs $31.6 million.”